The Polycomb Repressor Complex (PRC) plays a pivotal role in gene regulation during development and disease, with dysregulation contributing significantly to various human cancers. The intricate interplay between PRC and cellular signaling pathways sheds light on cancer complexity. PRC presents promising therapeutic opportunities, with inhibitors undergoing rigorous evaluation in preclinical and clinical studies. In this review, we emphasize the critical role of PRC complex in gene regulation, particularly PcG proteins mediated chromatin compaction through phase separation. We also highlight the pathological implications of PRC complex dysregulation in various tumors, elucidating underlying mechanisms driving cancer progression. The burgeoning field of therapeutic strategies targeting PRC complexes, notably EZH2 inhibitors, has advanced significantly. However, we explore the need for combination therapies to enhance PRC targeted treatments efficacy, providing a glimpse into the future of cancer therapeutics.
Keyphrases
- papillary thyroid
- squamous cell
- endothelial cells
- gene expression
- dna damage
- lymph node metastasis
- childhood cancer
- cancer therapy
- oxidative stress
- small molecule
- transcription factor
- squamous cell carcinoma
- long non coding rna
- mesenchymal stem cells
- dna methylation
- bone marrow
- epithelial mesenchymal transition
- cell therapy
- current status
- pluripotent stem cells